Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAS-Lynch
2024-516601-23-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in colon adenoma and hereditary nonpolyposis colorectal cancer (HNPCC) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Sep 2024; status: authorised.
02
Drugs
aspirin
03
Conditions
colon adenomahereditary nonpolyposis colorectal cancer (HNPCC)
Beyond the preview
Go deeper on 2024-516601-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516601-23-00.